Myelodysplastic syndromes

Annals of the New York Academy of Sciences

Volumn 1028, Issue , 2004, Pages 400-408

  Cilloni, Daniela ^a   Messa, Francesca ^a   Carturan, Sonia ^a   Arruga, Francesca ^a   Defilippi, Ilaria ^a   Messa, Emanuela ^a   Gottardi, Enrico ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Immunotherapy; Molecular biology of WT1; Myelodysplasia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CONFERENCE PAPER; GENE IDENTIFICATION; GENE TRANSLOCATION; IMMUNOTHERAPY; MOLECULAR BIOLOGY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; SIGNAL TRANSDUCTION;

EID: 14944375349     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.048     Document Type: Conference Paper

References (62)

1. HEANEY, M.L. et al. 1999. Myelodysplasia. N. Eng. J. Med. 340: 1649-1660.
2. MECUCCI, C. et al. 1992. Cytogenetics. Hematol. Oncol. Clin. North Am. 6: 523-541.
3. MARSHALL, C.J. et al. 1991. Tumor suppressor genes. Cell 64: 313-326.
4. PIERRE, R.V. et al. 1989. Clinical-cytogenetic correlation in myelodysplasia (preleukemia). Cancer Genet. Cytogenet. 40: 149-161.
5. MUFTI, G. 1992. Chromosomal deletions in the myelodysplastic syndromes. Leuk. Res. 40: 35-41.
6. BIANCHI, E. & L. ROGGE. 2003. Dissecting oncogenes and tyrosines kinases in AML cells. Med. Gen. Med. 21: 10.
7. CARTER, G. et al. 1992. Genetics lesions in preleukemia. Crit. Rev. Oncogenet. 3: 339-364.
8. BOULTWOOD, J. et al. 1995. Chromosomal deletions in myelodysplasia. Leuk. Lymphoma 17: 71-79.
9. LE BEAU, M.M. et al. 2001. Cytogenetics of myelodysplastic syndromes. Best Pract. Res. Clin. Haematol. 14479-14495.
10. THIRD MIC COOPERATIVE STUDY GROUP. 1987. Morphologic Immunologic and Cytogenetic (MIC) working classification. Of the primary myelodysplastic syndromes and therapy related myelodysplasias and leukemias. Cancer 32: 1-10
11. VAN DEN BERGHE, H. et al. 1985. The 5q- anomaly. Cancer Genet. Cytogenet. 17: 189-255.
12. VAN DEN BERGHE, H. et al. 1997. 5q-, twenty-five years later: a synopsis. Cancer Genet. Cytogenet. 94: 1-7.
13. WILLMAN, C.L. 1993. Deletion of IRF-1 mapping to chromosome 5q31.1 in human leukemia and preleukemic myelodysplasia. Science 259: 968-971.
14. LE BEAU, M.M. 1993. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA 90: 5484-5488.
15. LE BEAU, M.M. 1996. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid disorders. Blood 88: 1930-1935.
16. LAI, J.L. et al. 1995. Myelodysplastic syndromes and acute myeloid leukaemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 9: 370-381.
17. GOLUB, T.R. et al. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
18. RITCHIE, K.A. et al. 1995. The tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia 11: 1790-1783.
19. GOLUB, T.R. et al. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
20. SJOBLOM, T. et al. 1999. Characterization of the chronic myelomonocytic leukaemia associated TEL-PDGF beta R fusion protein. Oncogene 18: 7055-7062.
21. Ross, T.S. et al. 1998. Fusion of huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukaemia with t(5;7) (q33;q11.2). Blood 91: 4419-4426.
22. MAGNUSSON, M.K. et al. 2001. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98: 2518-2525.
23. KULKARNI, S. et al. 2000. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR/ABL-negative myeloproliferative disorders with a t(5:10)(q33:q21). Cancer Res. 60: 3592-3598.
24. ABE, A. et al. 1997. Fusion of the platelet-derived growth factor beta to a novel gene CEV in acute myelogenous leukaemia after clonal evolution. Blood 90: 4271-4277.
25. GUMBY, R.H. 2003. Sensitivity to Imatinib but low frequency of the TEL/PDGFRb fusion protein in chronic myelomonocytic leukaemia. Haematologica 88: 408-415.
26. KROGER, N. et al. 2002. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 118: 67-73.
27. APPERLEY, J.F. et al. 2002. Response to Imatinib mesylate in patients with chronic myeloproliferative diseases with the rearrangement of the platelet derived growth factor receptor beta. N. Engl. J. Med. 347: 481-487.
28. RUSSELL, M. et al. 1994. Expression of EVI1 in myelodysplastic syndromes and other haematological malignancies without 3q26 translocations. Blood 84: 1243-1248.
29. DREYFUS, F. et al. 1995. Expression of EVI-1 gene in myelodysplastic syndromes. Leukemia 9: 203-205.
30. JOLKOWSKA. J. et al. 2000. The EVI-1 gene-its role in pathogenesis of human leukemias. Leuk. Res. 24: 553-558.
31. NUCIFORA, G. et al. 1997. The EVI-1 gene in myeloid leukaemia. Leukemia 11: 2022-2031.
32. MORISHITA, K. et al. 1992. Activation of EVI-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc. Natl. Acad. Sci. USA 89: 3937-3941.
33. PINTADO, T. et al. 1985. Clinical correlation of he 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55: 535-541.
34. PADUA, R.A. et al. 2000. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br. J. Haematol. 111: 873-874.
35. PADUA, R.A. et al. 1998 RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10 year follow-up. Leukemia 12: 887-892.
36. PAQUETTE, R.L. et al. 1993. N-ras mutations are associated with poor prognosis and increased risk of leukaemia in myelodysplastic syndromes. Blood 82: 590-599.
37. GALLAGHER, A. et al. 1997. Ras and the myelodysplastic syndromes. Pathol. Biol. 45: 561-568.
38. BARBACID, M. 1987. ras genes. Annu. Rev. Biochem. 56: 779-827.
39. Bos, J.L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
40. NEUBAUER, A. et al. 1994. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukaemia. Blood 83: 1603-1611.
41. ADJEI, A.A., et al. 2000. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60: 1871-1877.
42. KARP, J.E. et al. 2001. Clinical and biological activity of the farnesyl transferase inhibitor R1 15777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical laboratory correlative trial. Blood 97: 3361-3369.
43. FELDMAN, E.J. et al. 2003. Continuous oral Lonafarnib (Sarasar) for the treatment of patients with myelodyspastic syndrome. Blood 102(Suppl.): Abstr. 1531.
44. LANCET, J.E. et al. 2003. Tipifarnib (ZARNESTRA) in previously untreated poor-risk AML and MDS: interim results of a phase 2 trial. Blood 102(Suppl.): Abstr. 613.
45. MORENO, I. et al. 2003. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukaemia. Haematologica 88: 19-24.
46. ABU-DUHIER, P.M. et al. 2001. Genomic structure of human FLT3: implications for mutational analysis. Br. J. Haematol. 113: 1076-1077.
47. HORIJKE, S. et al. 1997. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11: 1442-1446.
48. THIEDE, C. et al. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukaemia. Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335.
49. APPELBAUM, F.R. 2003. New targets for therapy in acute myeloid leukaemia. Leukemia 17: 492-495.
50. YEE, K.W. et al. 2002. SU5416 and SU5614 inhibit activity of wild type and mutant FLT3 receptor tyrosine kinase. Blood 100: 2941-2949.
51. KELLY, L.M. et al. 2002. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukaemia (AML). Cancer Cell 1: 421-432.
52. KARP, J.E. et al. 2001. Clinical and biologic activity of the farnesyl transferase inhibitor R1 15777 in adults with refractory and relapsed acute: a phase 1 clinical-laboratory correlative trial. Blood 97: 3361-3369.
53. URBAN, J.L. et al. 1992. Tumor antigen. Rev. Immunol. 10: 617-644.
54. VAN DEN EYNDE, B.J. et al. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9: 684-693.
55. ELISSEEVA, O.J. et al. 2002. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99: 3272-3279.
56. CALL, K.M. et al. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520.
57. BAIRD, P.N. et al. 1997 Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp. Hematol. 25: 312-320.
58. CILLONI, D. et al. 2002 Quantitative assessment of WT1 expression by RealTime-Q-PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16: 2115-2121.
59. INOUE, K. et al. 1996. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88: 2267-2278.
60. INOUE, K. et al. 1994. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 1405-1412.
61. CILLONI, D. et al. 2003. Usefulness of quantitative assessment of Wilms tumor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin. Hematol. 40: 37-41
62. CILLONI, D. et al. 2003. Very significant correlation between WT1 expression level and the IPSS score in patients with myelodysplastic syndromes. J. Clin. Oncol. 21: 1988-1995.